home / stock / ppbt / ppbt quote
Last: | $0.3626 |
---|---|
Change Percent: | -1.95% |
Open: | $0.3698 |
Close: | $0.369799 |
High: | $0.3698 |
Low: | $0.356 |
Volume: | 104,569 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.3626 | $0.3698 | $0.369799 | $0.3698 | $0.356 | 104,569 | 07-03-2024 |
$0.369799 | $0.3592 | $0.369799 | $0.3899 | $0.35 | 304,297 | 07-02-2024 |
$0.3591 | $0.35 | $0.3591 | $0.396 | $0.3356 | 815,082 | 07-01-2024 |
$0.407 | $0.428 | $0.407 | $0.45 | $0.4 | 935,854 | 06-28-2024 |
$0.4376 | $0.4711 | $0.4376 | $0.5 | $0.39 | 7,012,488 | 06-27-2024 |
$0.48 | $0.47 | $0.48 | $0.498 | $0.4073 | 151,780 | 06-26-2024 |
$0.47 | $0.52 | $0.47 | $0.529899 | $0.47 | 69,421 | 06-25-2024 |
$0.521556 | $0.516 | $0.521556 | $0.576 | $0.485 | 103,280 | 06-24-2024 |
$0.493 | $0.5092 | $0.493 | $0.51 | $0.47 | 124,798 | 06-21-2024 |
$0.4872 | $0.511 | $0.4872 | $0.55 | $0.485 | 137,614 | 06-20-2024 |
$0.505 | $0.555 | $0.505 | $0.5571 | $0.48 | 331,422 | 06-19-2024 |
$0.505 | $0.555 | $0.505 | $0.5571 | $0.48 | 331,422 | 06-18-2024 |
$0.54 | $0.591 | $0.54 | $0.62 | $0.52 | 226,291 | 06-17-2024 |
$0.601 | $0.6139 | $0.601 | $0.62 | $0.59 | 20,116 | 06-14-2024 |
$0.6185 | $0.62 | $0.6185 | $0.65 | $0.5801 | 97,613 | 06-13-2024 |
$0.605 | $0.59 | $0.605 | $0.63 | $0.58 | 46,204 | 06-12-2024 |
$0.575 | $0.56 | $0.575 | $0.63 | $0.55 | 103,577 | 06-11-2024 |
$0.5503 | $0.572 | $0.5503 | $0.6 | $0.55 | 116,148 | 06-10-2024 |
$0.572 | $0.6 | $0.572 | $0.66 | $0.55 | 148,728 | 06-07-2024 |
$0.615 | $0.6319 | $0.615 | $0.64 | $0.5801 | 64,345 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Purple Biotech Ltd ADR (Sponsored) Level 3 Company Name:
PPBT Stock Symbol:
NASDAQ Market:
Purple Biotech Ltd ADR (Sponsored) Level 3 Website:
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today anno...
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced ...
New data suggests that b aseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death...